#1 Clinical Trials Search in Europe

Cdr132L

CDR132L is an innovative drug currently being studied in clinical trials for its potential to treat various forms of heart failure. This synthetic antisense oligonucleotide (ASO) works by inhibiting microRNA-132-3p (miR-132), which plays a crucial role in cardiac remodeling and heart failure progression. The ongoing trials aim to assess the safety, efficacy, and pharmacological properties of CDR132L in patients with different types of heart conditions, including those who have recently experienced a heart attack or have stable heart failure.

Table of Contents

What is CDR132L?

CDR132L is a new medication being developed to treat various heart conditions. It is classified as a synthetic antisense oligonucleotide (ASO), which is a type of drug that can influence how genes work in our body[1]. Specifically, CDR132L is designed to selectively inhibit (or block) a molecule called microRNA-132-3p (miR-132)[1].

How CDR132L Works

CDR132L works by targeting a specific molecule in heart cells called miR-132. This molecule acts as a central switch that affects how certain genes behave in the heart. These genes are involved in processes that can lead to unhealthy changes in the heart’s structure and function, particularly after a heart attack or in cases of heart failure[1].

By inhibiting miR-132, CDR132L aims to:

  • Prevent or reverse harmful changes in the heart’s structure (called “cardiac remodeling”)
  • Reduce abnormal growth of heart muscle cells (called “hypertrophy”)
  • Improve the heart’s ability to pump blood effectively

Conditions Treated by CDR132L

CDR132L is being studied for several heart-related conditions:

  1. Heart Failure after Heart Attack: For patients who have reduced heart function (measured as Left Ventricular Ejection Fraction or LVEF) after experiencing a heart attack (myocardial infarction)[1].
  2. Heart Failure with Preserved Ejection Fraction (HFpEF): This is a type of heart failure where the heart’s pumping ability is normal or near-normal, but it has trouble filling with blood[2].
  3. Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF): This is a condition where the heart’s pumping ability is slightly reduced[2].
  4. Stable Heart Failure of Ischemic Origin: This refers to heart failure caused by reduced blood flow to the heart, typically due to coronary artery disease[3].

Clinical Trials of CDR132L

CDR132L is currently being tested in several clinical trials:

  1. Phase 2 Trial for Heart Failure after Heart Attack: This study is testing two different doses of CDR132L in patients who have reduced heart function after a heart attack. The main goal is to see if CDR132L can improve heart function and reduce the size of the heart’s left ventricle[1].
  2. Phase 2 Trial for HFpEF and HFmrEF: This study is looking at how CDR132L affects the structure and function of the heart in patients with preserved or mildly reduced heart function. It’s measuring things like heart muscle mass, the size of the heart’s chambers, and how well the heart relaxes and fills with blood[2].
  3. Phase 1 Trial for Stable Heart Failure: This early-stage trial is primarily focused on assessing the safety of CDR132L and how it’s processed by the body (pharmacokinetics) in patients with stable heart failure[3].

How CDR132L is Administered

In the clinical trials, CDR132L is being given as an intravenous (IV) injection. This means it’s delivered directly into a vein. The dosing schedule varies depending on the specific trial:

  • In some trials, it’s given as a single dose on specific days (like Day 1, Day 29, and Day 57)[1].
  • In others, it’s administered six times over the course of the study[2].

The exact dose is often calculated based on the patient’s body weight[1][2].

Safety and Side Effects

As CDR132L is still in clinical trials, its full safety profile is not yet known. The ongoing studies are carefully monitoring for any side effects or adverse events that may occur. One of the primary goals of these trials, especially the Phase 1 study, is to assess the safety and tolerability of CDR132L[3].

It’s important to note that in clinical trials, some patients receive a placebo (a harmless substance with no active ingredients) instead of the actual drug. This helps researchers accurately determine the effects of the medication being studied[1][2][3].

Aspect Details
Drug Name CDR132L
Drug Type Synthetic antisense oligonucleotide (ASO)
Mechanism of Action Selective inhibitor of microRNA-132-3p (miR-132)
Target Conditions Acute myocardial infarction, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
Administration Intravenous injection
Clinical Trial Phases Phase 1 and Phase 2
Primary Outcomes Safety, efficacy in improving heart function, changes in cardiac structure
Key Measurements Left ventricular volume, left ventricular mass, biomarker levels, cardiac imaging results

FAQ

  • What is CDR132L and how does it work? CDR132L is a synthetic antisense oligonucleotide (ASO) that selectively inhibits microRNA-132-3p (miR-132). It targets genes involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth, which contribute to heart failure progression. By inhibiting miR-132, CDR132L aims to improve heart function and reduce the negative effects of heart failure.
  • What types of heart conditions are being studied with CDR132L? CDR132L is being studied in clinical trials for various heart conditions, including acute myocardial infarction (heart attack), left-sided heart failure, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. These trials aim to assess its effectiveness in different stages and types of heart failure.
  • How is CDR132L administered to patients? CDR132L is administered intravenously (through a vein) in single doses. The dosage and frequency vary depending on the specific clinical trial. For example, in one study, patients receive doses on Day 1, Day 29, and Day 57, while another trial involves six doses over a longer period.
  • What are the main goals of the CDR132L clinical trials? The main goals of the CDR132L clinical trials are to assess its safety, efficacy, and pharmacological properties. Researchers are looking at various outcomes, including changes in heart structure and function, biomarker levels, and the drug's effects on cardiac remodeling. They also aim to determine the optimal dosage and administration schedule for the best results.
  • What are some of the measurements used to evaluate CDR132L's effectiveness? Researchers use various measurements to evaluate CDR132L's effectiveness, including echocardiography to assess left ventricular volume, cardiac magnetic resonance imaging to measure left ventricular mass and atrial volume, and blood tests to check levels of biomarkers such as N-terminal pro B-type natriuretic peptide and high-sensitivity cardiac troponin T. They also monitor patients for any adverse events to ensure the drug's safety.

Ongoing Clinical Trials on Cdr132L

  • Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Greece Hungary The Netherlands Poland +1

Glossary

  • Antisense Oligonucleotide (ASO): A synthetic piece of DNA or RNA that can bind to specific molecules of RNA, blocking their ability to make proteins or changing how they are processed.
  • microRNA-132-3p (miR-132): A small RNA molecule that plays a role in regulating gene expression, particularly in cardiac cells. It is involved in processes that can lead to heart failure.
  • Cardiac Remodeling: Changes in the size, shape, structure, and function of the heart, often occurring after heart injury or during heart failure.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction. It's used to diagnose and track heart failure.
  • Myocardial Infarction (MI): Commonly known as a heart attack, it occurs when blood flow to part of the heart muscle is blocked, causing damage to the heart tissue.
  • Heart Failure with Preserved Ejection Fraction (HFpEF): A type of heart failure where the heart's ability to pump blood is normal, but it has trouble relaxing and filling with blood.
  • Echocardiography: An imaging technique that uses sound waves to create pictures of the heart, allowing doctors to see its structure and function.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Biomarker: A measurable substance in the body that can indicate the presence or severity of a disease or the effects of a treatment.

References

  1. https://clinicaltrials.eu/trial/study-on-the-effects-of-cdr132l-in-patients-with-reduced-heart-function-after-a-heart-attack/
  2. https://clinicaltrials.gov/study/NCT05953831
  3. https://clinicaltrials.gov/study/NCT04045405